115 related articles for article (PubMed ID: 12636056)
1. A new modification of the Chiron ACS assay for total prostate-specific antigen achieves equimolar response characteristics and improves the detection of prostate cancer.
Oberpenning F; Weining C; Brandt B; De Angelis G; Heinecke A; Hamm M; Stieber P; Hertle L; Schmid HP; Semjonow A
Clin Chem Lab Med; 2003 Jan; 41(1):90-4. PubMed ID: 12636056
[TBL] [Abstract][Full Text] [Related]
2. Methodological and clinical comparison of the ACS prostate-specific antigen assay and the Tandem-E prostate-specific antigen assay in prostate cancer.
Schambeck CM; Schmeller N; Stieber P; Jansen HM; Pahl H; Schneider W; Fateh-Moghadam A
Urology; 1995 Aug; 46(2):195-9. PubMed ID: 7542821
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the clinical performance of equimolar- and skewed-response total prostate-specific antigen assays versus complexed and free PSA assays and their ratios in discriminating between benign prostatic hyperplasia and prostate cancer.
Wians FH; Cheli CD; Balko JA; Bruzek DJ; Chan DW; Sokoll LJ
Clin Chim Acta; 2002 Dec; 326(1-2):81-95. PubMed ID: 12417099
[TBL] [Abstract][Full Text] [Related]
4. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement.
Onur R; Ilhan N; Orhan I; Ilhan N
World J Urol; 2003 May; 21(1):43-7. PubMed ID: 12756494
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 3 investigational assays for the free form of prostate specific antigen.
Nixon RG; Meyer GE; Blase AB; Gold MH; Brawer MK
J Urol; 1998 Aug; 160(2):420-5. PubMed ID: 9679890
[TBL] [Abstract][Full Text] [Related]
6. Comparison between equimolar- and skewed-response assays of prostate specific antigen: is there an influence on the clinical significance when measuring total serum prostate specific antigen?
Jung K; Lein M; Schnorr D; Brux B; Henke W; Loening S
Ann Clin Biochem; 1996 May; 33 ( Pt 3)():209-14. PubMed ID: 8791983
[TBL] [Abstract][Full Text] [Related]
7. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system.
Vashi AR; Wojno KJ; Henricks W; England BA; Vessella RL; Lange PH; Wright GL; Schellhammer PF; Weigand RA; Olson RM; Dowell BL; Borden KK; Oesterling JE
Urology; 1997 Jan; 49(1):19-27. PubMed ID: 9000179
[TBL] [Abstract][Full Text] [Related]
8. Assessing the clinical impact of prostate-specific antigen assay variability and nonequimolarity: a simulation study based on the population of the United Kingdom.
Roddam AW; Price CP; Allen NE; Ward AM
Clin Chem; 2004 Jun; 50(6):1012-6. PubMed ID: 15031266
[TBL] [Abstract][Full Text] [Related]
9. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
[TBL] [Abstract][Full Text] [Related]
10. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
[TBL] [Abstract][Full Text] [Related]
11. Total and free PSA: a methodical and clinical evaluation of five assays.
Reiter W; Stieber P; Schmeller N; Nagel D; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1997; 17(6D):4759-65. PubMed ID: 9494603
[TBL] [Abstract][Full Text] [Related]
12. Free and complexed prostate-specific antigen (PSA) in the early detection of prostate cancer.
Tello FL; Prats CH; González MD
Clin Chem Lab Med; 2001 Feb; 39(2):116-20. PubMed ID: 11341744
[TBL] [Abstract][Full Text] [Related]
13. Multiple forms of prostate-specific antigen in serum: differences in immunorecognition by monoclonal and polyclonal assays.
Zhou AM; Tewari PC; Bluestein BI; Caldwell GW; Larsen FL
Clin Chem; 1993 Dec; 39(12):2483-91. PubMed ID: 7504592
[TBL] [Abstract][Full Text] [Related]
14. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
15. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
[TBL] [Abstract][Full Text] [Related]
17. Analytical performance and clinical validity of two free prostate-specific antigen assays compared.
Jung K; Stephan C; Lein M; Henke W; Schnorr D; Brux B; Schürenkämper P; Loening SA
Clin Chem; 1996 Jul; 42(7):1026-33. PubMed ID: 8674185
[TBL] [Abstract][Full Text] [Related]
18. Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project.
Lazzeri M; Haese A; Abrate A; de la Taille A; Redorta JP; McNicholas T; Lughezzani G; Lista G; Larcher A; Bini V; Cestari A; Buffi N; Graefen M; Bosset O; Le Corvoisier P; Breda A; de la Torre P; Fowler L; Roux J; Guazzoni G
BJU Int; 2013 Aug; 112(3):313-21. PubMed ID: 23826841
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
[TBL] [Abstract][Full Text] [Related]
20. [Value of free/total prostate specific antigen in the early diagnosis of prostate cancer (study of 105 patients)].
de la Taille A; Houlgatte A; Houdelette P; Berlizot P; Ramirez J; Ricordel I
Prog Urol; 1997 Apr; 7(2):240-5. PubMed ID: 9264766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
